Member Info for Dr_Horrible

RNS
· Exclusive Distribution Agreement for Fruitflow+ Omega-3 in China through the Chinese Cross-Border e-commerce channel ('CBEC') secured in November 2020, first test order has been placed.

Store Contact Us:
Light Network cross-border e-commerce direct purchase. China.

Light Network is a better translation.

The Contact Us page says:

Lightluosu cross-border e-commerce direct purchase.

China

We may be much closer to approval than we thought looking at those timescales. 15 months +.

Was it Feb 2019 they submitted the trial evidence? 25 months ago?

Very odd that they would carry out a major study into FF affect on blood lipids, then release a new blood lipids product without it included. It may be that they are anticipating blue hat for FF by the launch date, but don’t want to put it on the tin yet, as it is commercially sensitive.

DSM currently $31.5bn according to T212 info and Siri converting.

DSM is much bigger than By-Health.

I hope your wrong everhopeful. PXS could make us a fortune in future if it is not bought out.

Is it significant multiples from By-Health alone?

So we are in a position to make good profit from future orders. I’m hoping and expecting that PXS will be in a much better place in 2 to 3 years.

Can’t locate it. I think it’s gone now.

I don’t suppose anybody has a copy of the podcast type interview that Stephen Moon did back in around 2010/11, where he talked about the profit sharing agreement with DSM?

As I recall the agreement is weighted towards DSM up to a particular volume (confidential), as they need to recover costs and make it with worth while their investment. Then as volumes rise, Provexis get a larger part of the share on a sliding scale. Also, as volumes rise the margin on FF goes from OK to very high. That is because the base manufacturing costs are high, but don’t rise much, and the materials (tomato seeds) are a by-product of other products.

So as I see it, DSM currently takes the lions share with low margin at the moment, but we expect that to switch around quite quickly as volumes rise.

Do others recall that?

It keeps me hopeful that PXS will see a large income from the By-Health orders and other brands that are part of large global businesses.

Also, thinking about the PE ratio. If you look at the health/drug/medical sector, the ratios can be crazy high, 40 to 80 being pretty normal. So PXS share price could absolutely rocket on big FF orders. We could quite easily see £5m profit and £175m market cap.

That’s my thought of the day! But as Gix likes to say, BWTFDIK

I don’t want a take-over. I would like the company to be successful and well valued before any such deal is ever considered.

By-Health are DSM’s customer. DSM share profits with Provexis.

They used to say it was Heart Health month, but don’t seem to bother with that anymore. No other relevance that I’m aware of. Next update may be September if anything like last year.

Good info there Gix. We should find out soon.

When does 3 to 4 years start? Before the trials? After the application submission.? We’re a few years into the whole process.

This suggests it costs a fortune and takes 3 to 4 years.

https://www.nutraingredients-asia.com/Article/2019/04/08/Daigou-and-direct-selling-clampdown-in-China-growing-pains-but-market-will-still-thrive-HPA

1 SAMR application early 2019, one later in 2019. How long does it take? How long is a piece of string?

From 2018:

Two studies have been successfully completed in China, one study is currently ongoing at a Chinese clinical site and three further planned human studies in 2019 have been confirmed by BY-HEALTH.



The two completed studies (a human study and an animal study) showed excellent results in use for Fruitflow®, and BY-HEALTH intends to make its first blue cap submission to the SAMR for Fruitflow® in February 2019, with a further blue cap submission envisaged later in 2019, both to include references to the Company's existing European Food Safety Authority ('EFSA') health claim for Fruitflow.

More than 10 years.